In This Article:
As global markets show signs of recovery, with U.S. stocks rebounding and growth stocks outperforming value shares, the focus on companies with strong insider ownership becomes increasingly relevant. High insider ownership often signals confidence in a company's future prospects, making these firms particularly attractive during periods of market optimism and economic adjustments.
Top 10 Growth Companies With High Insider Ownership
| Name | Insider Ownership | Earnings Growth |
| Lavvi Empreendimentos Imobiliários (BOVESPA:LAVV3) | 11.9% | 21.1% |
| Clinuvel Pharmaceuticals (ASX:CUV) | 10.4% | 27.4% |
| Atlas Energy Solutions (NYSE:AESI) | 29.1% | 42.1% |
| Medley (TSE:4480) | 34% | 30.4% |
| KebNi (OM:KEBNI B) | 37.8% | 86.1% |
| Credo Technology Group Holding (NasdaqGS:CRDO) | 14.1% | 95% |
| Adocia (ENXTPA:ADOC) | 11.9% | 63% |
| Adveritas (ASX:AV1) | 21.1% | 144.2% |
| HANA Micron (KOSDAQ:A067310) | 18.3% | 100.3% |
| UTI (KOSDAQ:A179900) | 33.1% | 134.6% |
We're going to check out a few of the best picks from our screener tool.
Pharma Mar
Simply Wall St Growth Rating: ★★★★★☆
Overview: Pharma Mar, S.A. is a biopharmaceutical company focused on the research, development, production, and commercialization of bio-active principles for oncology across various regions including Europe and the United States, with a market cap of €833.45 million.
Operations: The company generates €194.09 million in revenue from its oncology segment.
Insider Ownership: 11.9%
Pharma Mar, S.A. presents a mixed picture for growth investors with high insider ownership. Despite a highly volatile share price over the past three months, the company is expected to see revenue growth of 18.2% per year, outpacing the Spanish market's 4.8%. Earnings are forecast to grow at 55.24% annually, and it is projected to become profitable within three years with a high return on equity (34.4%). However, recent earnings show a decline in net income from €6.44 million to €3.54 million year-over-year despite stable revenue (€80.84 million).
-
Delve into the full analysis future growth report here for a deeper understanding of Pharma Mar.
-
Upon reviewing our latest valuation report, Pharma Mar's share price might be too pessimistic.
APT Medical
Simply Wall St Growth Rating: ★★★★★★
Overview: APT Medical Inc. engages in the research, development, manufacturing, and supply of electrophysiology and vascular interventional medical devices in China with a market cap of CN¥32.61 billion.
Operations: APT Medical's revenue from medical products is CN¥1.86 billion.
Insider Ownership: 31.6%